Cargando…

Fidelity of peripheral blood for monitoring genomics and tumor immune‐microenvironment in myelodysplastic syndromes

The aim of this study is to investigate whether the peripheral blood (PB) can serve as a surrogate immune‐microenvironment to bone marrow for genetic and immune monitoring in myelodysplastic syndrome (MDS). We compared the composition of T cell subsets and somatic mutation burden in 36 pairs of PB a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sung‐Eun, Wang, Feng, Trujillo‐Ocampo, Abel, Ruiz‐Vasquez, Wilfredo, Cho, Hyun‐Woo, Takahashi, Koichi, Molldrem, Jeffrey J., Futreal, Andrew, Garcia‐Manero, Guillermo, Im, Jin S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175915/ https://www.ncbi.nlm.nih.gov/pubmed/35844984 http://dx.doi.org/10.1002/jha2.112

Ejemplares similares

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA(-)CD62L(+)CD4(+) Invariant NKT Cells With Th-2 Biased Cytokine Production Profile
por: Trujillo-Ocampo, Abel, et al.
Publicado: (2020)

Corrigendum: IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA(-)CD62L(+)CD4(+) Invariant NKT Cells With Th-2 Biased Cytokine Production Profile
por: Trujillo-Ocampo, Abel, et al.
Publicado: (2021)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
por: Rodriguez-Sevilla, Juan Jose, et al.
Publicado: (2023)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

Increased fidelity of protein synthesis extends lifespan
por: Martinez-Miguel, Victoria Eugenia, et al.
Publicado: (2021)

The microenvironment in myelodysplastic syndromes: From concept to therapeutic target
por: Raaijmakers, Marc H.G.P.
Publicado: (2018)

Fidel Velázquez y los intelectuales /
por: Amilpa Trujillo, Fernando
Publicado: (1992)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast
por: Carrocci, Tucker J., et al.
Publicado: (2017)

Clasp2 ensures mitotic fidelity and prevents differentiation of epidermal keratinocytes
por: Shahbazi, Marta N., et al.
Publicado: (2017)

Décimas para Fidel /
por: Cházaro Lagos, Guillermo, 1919-
Publicado: (2007)

PB2019: PHASE 1B CLINICAL STUDY OF IRAK 1/4 INHIBITION FOR LOW-RISK MYELODYSPLASTIC SYNDROMES REFRACTORY/RESISTANT TO PRIOR THERAPIES: A TRIAL IN PROGRESS
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

NMD monitors translational fidelity 24/7
por: Celik, Alper, et al.
Publicado: (2017)

Fatigue, symptom burden, and health‐related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria
por: Escalante, Carmen P., et al.
Publicado: (2019)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2
por: Herrmann, Amanda C., et al.
Publicado: (2019)

Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2019)

Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype
por: Mallo, Mar, et al.
Publicado: (2023)

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
por: Ma, Wanlong, et al.
Publicado: (2010)

Factors contributing to intervention fidelity in a multi-site chronic disease self-management program
por: Perrin, Karen M, et al.
Publicado: (2006)

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
por: Silverman, LR, et al.
Publicado: (2008)

DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population
por: Belickova, Monika, et al.
Publicado: (2013)

Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group
por: Heilig, Christoph E, et al.
Publicado: (2010)

Identification of Novel Insertions and Deletions in Haematopoietic Stem/Progenitor Cells in de novo Myelodysplastic Syndromes
por: Bandara, Manoj, et al.
Publicado: (2021)

Favorable prognostic phenotype in myelodysplastic syndrome with der(1;7)(q10;p10)
por: Horio, Tomohiro, et al.
Publicado: (2020)

Increased Expression of Interferon Signaling Genes in the Bone Marrow Microenvironment of Myelodysplastic Syndromes
por: Kim, Miyoung, et al.
Publicado: (2015)

Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes
por: Mian, Syed A., et al.
Publicado: (2021)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

The value of minilaparotomy for total hysterectomy for benign uterine disease: A comparative study with conventional Pfannenstiel and laparoscopic approaches
por: Royo, Pedro, et al.
Publicado: (2009)

Peripheral Venous Pressure as a Predictor of Central Venous Pressure in Continuous Monitoring in Children
por: Amoozgar, H, et al.
Publicado: (2011)

Using High-Fidelity Simulation to Teach Ethics Related Non-Technical Skills: Description of an Innovative Model
por: Tanoubi, Issam, et al.
Publicado: (2020)

Los "San Lunes" de Fidel.
por: Prieto, Guillermo, 1818-1897
Publicado: (1948)

Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning
por: Sallman, David A., et al.
Publicado: (2022)

RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression
por: Lakshmikuttyamma, Ashakumary, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_v4djjbegvp14uan1l4d691c4k3